Viridian Therapeutics, Inc.
VRDN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,301,375 | $974,774 | $937,270 | $235,633 |
| - Cash | $99,594 | $102,827 | $155,579 | $42,299 |
| + Debt | $21,095 | $21,048 | $5,258 | $520 |
| Enterprise Value | $1,222,876 | $892,995 | $786,949 | $193,854 |
| Revenue | $302 | $314 | $1,772 | $2,963 |
| % Growth | -3.8% | -82.3% | -40.2% | – |
| Gross Profit | $302 | $314 | $1,772 | $2,963 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$265,663 | -$235,365 | -$129,133 | -$79,290 |
| % Margin | -87,967.9% | -74,957% | -7,287.4% | -2,676% |
| Net Income | -$269,949 | -$237,734 | -$129,874 | -$79,413 |
| % Margin | -89,387.1% | -75,711.5% | -7,329.2% | -2,680.2% |
| EPS Diluted | -3.98 | -5.31 | -3.91 | -6.66 |
| % Growth | 25% | -35.8% | 41.3% | – |
| Operating Cash Flow | -$232,319 | -$184,170 | -$93,838 | -$54,581 |
| Capital Expenditures | -$511 | -$898 | -$797 | -$338 |
| Free Cash Flow | -$232,830 | -$185,068 | -$94,635 | -$54,919 |